Ana Herrero Mier

  • IBBTEC. C/ Albert Einstein 22, PCTCAN, 39011 Santander (SPAIN)
  • ana.herrero@unican.es
  • 942 206 799 ext. 25907
  • Spatial Regulation of Ras-ERK Signals in Cancer
  • Cancer
  • Department of Cell & Molecular Signalling
Ana Herrero got her BSc in Biochemistry from the Universidad Autónoma de Madrid (2006) and joined Piero Crespo´s group (CSIC/Universidad de Cantabria) for undertaking a predoctoral position with a FPU (Formación de Profersorado Universitario) fellowship. In 2013, after finishing her doctoral thesis in the study of RAS/ERK signals in carcinogenesis, she joined Prof. Walter Kolch´s group in Systems Biology Ireland (Dublin) for starting her postdoctoral formation. There, Ana studied RAS signalling from different subcellular localization by applying a broad range of biomolecular and biological techniques. In 2016, she obtained a position at Prof. Margaret Frame´s group in Edinburgh Cancer Research Centre (Scotland, UK) for continuing her postdoctoral formation. During that scientific stage, Ana worked on the study of adhesion proteins´ nuclear role, and characterised new ILK functions in distant regions from its canonical site. In 2018, she was awarded a Juan de la Cierva-Incorporación fellowship that allowed her to generate the preliminary data for developing her own research line. Now, her project is about to study RAS-ERK regulatory mechanisms by ncRNAs.
Ana is co-author in some scientific article published in prestigious journals such as Cancer Cell, Cell Reports, Nature Communication, etc., both as first author or as collaborative authorship. She has participated in different international and national congresses and conferences, and she has contributed to the formation of young scientists and co-direction of doctoral thesis.

​Spatial Regulation of Ras-ERK Signals in Cancer


Research lines 

    • Spatial regulation of Ras-ERK signals in physiological processes and in cancer
    • Development of antitumoral drugs targeting protein-protein interactions in the Ras-ERK pathway


Funding

    • “Nuevas dianas moleculares en la ruta Ras-ERK: potencial terapéutico en el cáncer de tiroides”. Asociación Española Contra el Cáncer (AECC). GCB141423113. Proyecto coordinado 2014-2019. 
    • Red Temática de Investigación Cooperativa sobre el Cáncer (RTICC). RD/12/0036/0033. 2012-2015.
    • “Proteínas Scaffold como moduladores de la resistencia a inhibidores de la ruta RAS-ERK en melanoma”.  SAF-2015 63638R.  2016-2018.
    • Grupo incluido en: Centro de Investigación Biomédica en Red sobre el Cáncer (CIBERONC). (CB16/12/00436). 2017-2023.
    • “ERK spatial distribution and dimerization: implications in carcinogenesis”. RTI2018-096658B. 2019-2021.
    • “Repurposing MAPK inhibitors for the treatment of COVID-19”. Proyecto intramural CSIC. CSIC-COV19-095. 2020.
    • Grupo incluido en la Plataforma PTI SALUD GLOBAL-CSIC: SG2103031_2107300020.
    • “Reutilización de inhibidores de MAPK para el tratamiento de COVID-19”. G.CANTABRIA: 2020UIC22-PUB0008.
    • “Proteínas HOX como mediadores de la ruta RAS-ERK”. PID2021-126288OB-I00. 2022-2025. 294.000€. Investigador Principal.
    • “Desarrollo de un marcador de la respuesta terapéutica del melanoma BRAF positivo”. Proyectos de Prueba de Concepto PDC2022-133569-I00. 2023-2025.



Piero Crespo Baraja (IP)

View more

Lorena Agudo Ibáñez

View more

Rocío García Gómez

View more

Daniel Molina Carreño

View more

Marta Morante Ezquerra

View more

Laura Ruiz Peinado

View more